Key result
CC-chemokine receptor inhibitor Met-RANTES reveals these receptors as potential therapeutic targets in Chagas disease.
Why the study?
The pathogenesis of Trypanosoma cruzi-elicited myocarditis and the role of CC-chemokines and their receptors in inflammation and heart dysfunction require further understanding to develop new therapeutic strategies.
CC-chemokine receptors, specifically targeted by inhibitors like Met-RANTES, represent a potential therapeutic target for ameliorating inflammation in Trypanosoma cruzi-elicited myocarditis.
Answers are grounded in this paper and cite their sources.
Supports CC-chemokine receptor targeting in Chagas disease; leaves open clinical translation from experimental models.
The comprehension of the pathogenesis of Trypanosoma cruzi-elicited myocarditis is crucial to delineate new therapeutic strategies aiming to ameliorate the inflammation that leads to heart dysfunction, without hampering parasite control. The augmented expression of CCL5/RANTES and CCL3/MIP-1alpha, and their receptor CCR5, in the heart of T. cruzi-infected mice suggests a role for CC-chemokines and their receptors in the pathogenesis of T. cruzi-elicited myocarditis. Herein, we discuss our recent results using a CC-chemokine receptor inhibitor (Met-RANTES), showing the participation of CC-chemokines in T. cruzi infection and unraveling CC-chemokine receptors as an attractive therapeutic target for further evaluation in Chagas disease.
No takes yet. Share an insight, caveat, or question.
Marino et al. (2005) conducted a review in Trypanosoma cruzi-elicited myocarditis. CC-chemokine receptor inhibitor (Met-RANTES) was evaluated. A CC-chemokine receptor inhibitor (Met-RANTES) demonstrated the participation of CC-chemokines in T. cruzi infection, highlighting these receptors as potential therapeutic targets in Chagas disease.
Synapse has enriched 10 related papers. Consider them for comparative context: